Product Description:

• Recombinant methionylated human granulocyte-colony stimulating factor (G-CSF) produced in E. coli by recombinant DNA technology.
• IHuman G-CSF is a glycoprotein which regulates the production and release of functional neutrophils from the bone marrow. Filgrastim Solution for Injection containing r-metHuG-CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes.

How to use:

• Filgrastim may be given as a 30-minute or 24-hour intravenous infusion or given by continuous 24-hour subcutaneous infusion.
• Filgrastim should be diluted in 20 mL of 5% glucose solution.

Caution & Warnings:

• Hypersensitivity to the active substance or to any of the excipients.

Side Effects:

• Anaphylactic reaction, serious pulmonary adverse events (including interstitial pneumonia and ARDS), capillary leak syndrome, severe splenomegaly/splenic rupture, transformation to myelodysplastic syndrome or leukaemia in SCN patients, GvHD in patients receiving allogeneic bone marrow transfer or peripheral blood cell progenitor cell transplant and sickle cell crisis in patients with sickle cell disease.
• The most commonly reported adverse reactions are pyrexia, musculoskeletal pain (which includes bone pain, back pain, arthralgia, myalgia, pain in extremity, musculoskeletal pain, musculoskeletal chest pain, neck pain), anaemia, vomiting, and nausea.

Ingredients:

• Filgrastim 30mu/0.5ml.